Amit D. Munshi is the Chairman of Zura Board of Directors. Most recently, Mr. Munshi was President and Chief Executive Officer of Arena Pharmaceuticals Inc. from May 2016 to March 2022 and a member of the Board of Directors from June 2016 until March 2022, when Arena Pharmaceuticals was sold to Pfizer Inc. Previously, Mr. Munshi served as President and Chief Executive Officer and as a director of 288 Epirus Biopharmaceuticals, Inc., a biopharmaceutical company focused on biosimilars, and Percivia LLC, a biotechnology company which was sold to Johnson & Johnson. Subsequent to an asset sale, in July 2016, Epirus filed a voluntary Chapter 7 petition in the United States Bankruptcy Court for the District of Massachusetts. Prior to Epirus and Percivia, Mr. Munshi was a co-founder and served as Chief Business Officer of Kythera Biopharmaceuticals, Inc. from 2005 to 2010, which was sold to Allergan plc, and held multiple leadership positions at Amgen Inc. from 1997 to 2005, including General Manager, Nephrology Europe. He has served as the Chairman of the Board of Enterprise Therapeutics since January 2020.
Simultaneously, Mr. Munshi has also served as a member of the Board of Directors and Audit Committee of Galecto Inc. (GLTO) since January 2020. Mr. Munshi likewise served as a member of the Board and Audit Committee of Pulmatrix Inc. (PULM) from June 2017 until March 2021. Additionally, Mr. Munshi currently serves as a director of two U.S. subsidiaries of Zura: Zura Bio Inc. and Z33 Bio Inc. Mr. Munshi holds a B.S. in Economics and a B.A. in History from the University of California, Riverside, and an M.B.A. from the Peter F. Drucker School of Management at Claremont Graduate University. Mr. Munshi has more than 30 years of global biopharmaceutical industry experience in executive management, business development, product development and portfolio management. Mr. Munshi’s vast executive management and business experience in the global biopharmaceutical industry and in-depth knowledge of product development gives him the qualifications, attributes and skills to serve as one of our directors.
What is Amit Munshi's net worth?
The estimated net worth of Amit Munshi is at least $4.75 million as of April 22nd, 2024. Munshi owns 777,384 shares of Zura Bio stock worth more than $4,749,816 as of April 1st. This net worth evaluation does not reflect any other investments that Munshi may own. Learn More about Amit Munshi's net worth.
How do I contact Amit Munshi?
Has Amit Munshi been buying or selling shares of Zura Bio?
Amit Munshi has not been actively trading shares of Zura Bio in the last ninety days. Most recently, on Monday, April 22nd, Amit Munshi bought 159,744 shares of Zura Bio stock. The stock was acquired at an average cost of $3.13 per share, with a total value of $499,998.72. Following the completion of the transaction, the director now directly owns 777,384 shares of the company's stock, valued at $2,433,211.92. Learn More on Amit Munshi's trading history.
Who are Zura Bio's active insiders?
Are insiders buying or selling shares of Zura Bio?
During the last year, Zura Bio insiders bought shares 1 times. They purchased a total of 2,000,000 shares worth more than $12,500,000.00. The most recent insider tranaction occured on February, 26th when Major Shareholder Ai Biotechnology Llc bought 2,000,000 shares worth more than $12,500,000.00. Insiders at Zura Bio own 22.1% of the company.
Learn More about insider trades at Zura Bio. Information on this page was last updated on 2/26/2026.
